Health Ministry allows holding int'l stage of clinical trials of Chinese coronavirus vaccine Ad5-nCov in Russia - Petrovax
MOSCOW. Dec 7 (Interfax) - The Russian Health Ministry has allowed holding the third international phase of clinical trials of the Chinese coronavirus vaccine Ad5-nCov in Russia with the participation of 8,000 volunteers, the Petrovax company told Interfax on Monday.
"The Health Ministry has allowed Russia's participation in the massive international multi-center randomized placebo-controlled third phase of clinical trials of the efficacy and immunogenicity of the candidate coronavirus vaccine Ad5-nCov made by CanSino Biologics (CanSinoBIO) (SHSE: 688185, HKEX:06185). The international trials are conducted in partnership with Petrovax," the company said on Monday.
The clinical trials are expected to involve 8,000 volunteers from Russia. On the whole, more than 40,000 volunteers aged 18 and up will be participating in the trials. An international group of scientists will evaluate vaccination results.
According to Petrovax, the first groups of volunteers participating in the international stage of clinical trials of the candidate coronavirus vaccine Ad5-nCov designed by CanSino Biologics Inc. have been successfully vaccinated.
"The volunteers are fine, and none of them has adverse side-effects," Petrovax said.